{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/PLYX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T12:45:03.594Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11027,"canonical_name":"Polaryx Therapeutics, Inc.","cik":"0002075320","uei":null,"lei":null,"duns":null,"ticker":"PLYX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":10,"clinical":2},"count":12,"timeline":[{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Polaryx Therapeutics, Inc. — 2026-09-14","url_slug":"/sec/cik-0002075320/8-k/0001213900-26-099416","accession_number":"0001213900-26-099416","importance":35},{"ts":"2026-09-01","kind":"sec.filing","form_type":"8-K","title":"8-K — Polaryx Therapeutics, Inc. — 2026-09-01","url_slug":"/sec/cik-0002075320/8-k/0001213900-26-096235","accession_number":"0001213900-26-096235","importance":35},{"ts":"2026-08-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Polaryx Therapeutics, Inc. — 2026-08-13","url_slug":"/sec/cik-0002075320/10-q/0001213900-26-089118","accession_number":"0001213900-26-089118","importance":45},{"ts":"2026-07-31","kind":"clinical.trial","reporter":"Polaryx Therapeutics, Inc.","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07740512","excerpt":"[\"Lysosomal Storage Disorders\",\"Sandhoff Disease\",\"Krabbe Disease\",\"CLN2\",\"CLN3\"]","importance":45},{"ts":"2026-07-28","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Polaryx Therapeutics, Inc. — 2026-07-28","url_slug":"/sec/cik-0002075320/def-14a/0001213900-26-082339","accession_number":"0001213900-26-082339","importance":40},{"ts":"2026-07-28","kind":"sec.filing","form_type":"ARS","title":"ARS — Polaryx Therapeutics, Inc. — 2026-07-28","url_slug":"/sec/cik-0002075320/ars/0001213900-26-082353","accession_number":"0001213900-26-082353","importance":30},{"ts":"2026-07-28","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Polaryx Therapeutics, Inc. — 2026-07-28","url_slug":"/sec/cik-0002075320/defa14a/0001213900-26-082345","accession_number":"0001213900-26-082345","importance":30},{"ts":"2026-07-24","kind":"sec.filing","form_type":"S-8","title":"S-8 — Polaryx Therapeutics, Inc. — 2026-07-24","url_slug":"/sec/cik-0002075320/s-8/0001213900-26-081404","accession_number":"0001213900-26-081404","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"8-K","title":"8-K — Polaryx Therapeutics, Inc. — 2026-07-21","url_slug":"/sec/cik-0002075320/8-k/0001213900-26-080041","accession_number":"0001213900-26-080041","importance":35},{"ts":"2026-07-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Polaryx Therapeutics, Inc. — 2026-07-17","url_slug":"/sec/cik-0002075320/8-k/0001213900-26-078912","accession_number":"0001213900-26-078912","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Polaryx Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0002075320/10-q/0001213900-26-056973","accession_number":"0001213900-26-056973","importance":45},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Polaryx Therapeutics, Inc.","title":"Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT04637282","excerpt":"[\"Juvenile Neuronal Ceroid Lipofuscinosis\"]","importance":60}]}